-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Abf3hW0XcdBBbh1n++3jjmJgWm0d1ss44HJtguW7tx7xW3jnfBTq3ZxnSNRDz2wn
 oc74CSvvsvR9rZ08qeQgLw==

<SEC-DOCUMENT>0001079973-08-000621.txt : 20080626
<SEC-HEADER>0001079973-08-000621.hdr.sgml : 20080626
<ACCEPTANCE-DATETIME>20080626143348
ACCESSION NUMBER:		0001079973-08-000621
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080626
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080626
DATE AS OF CHANGE:		20080626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AspenBio Pharma, Inc.
		CENTRAL INDEX KEY:			0001167419
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				841553387
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33675
		FILM NUMBER:		08919098

	BUSINESS ADDRESS:	
		STREET 1:		1585 S. PERRY STREET
		CITY:			CASTLE ROCK
		STATE:			CO
		ZIP:			80104
		BUSINESS PHONE:		(303) 794-2000

	MAIL ADDRESS:	
		STREET 1:		1585 S. PERRY STREET
		CITY:			CASTLE ROCK
		STATE:			CO
		ZIP:			80104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASPENBIO INC
		DATE OF NAME CHANGE:	20020213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>appy_8k-062608.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>AspenBio Pharma, Inc. Form 8-K</TITLE>
</HEAD>
<BODY>


<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>UNITED STATES <BR>SECURITIES AND EXCHANGE
COMMISSION
<BR>Washington, D.C. 20549</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>FORM 8-K</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>CURRENT REPORT</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>Pursuant to Section 13
OR 15(d) of <BR>The Securities Exchange
Act of 1934</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Project" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Date
of Report (Date of earliest event reported) &nbsp;&nbsp;
June 26, 2008</B> </FONT> </P>






<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH></TH>
     <TH></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="99%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>AspenBio Pharma, Inc.  </B></U></FONT></TD>
     <TD WIDTH="1%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Exact name of registrant as specified in charter)
</FONT></TD>
     <TD ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
</FONT></TD></TR>
</TABLE>
<BR>







<TABLE WIDTH="100%" CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER">
<TR VALIGN="BOTTOM">
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="34%" ALIGN="Center">
<FONT FACE="Times New Roman, Times, Serif" SIZE="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><B>Colorado </B></U><B>&nbsp;&nbsp;&nbsp;<BR>
(State or other jurisdiction</B><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>of incorporation)</B> </FONT>
</TD>
     <TD WIDTH="33%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="3">&nbsp;&nbsp;<U><B>001-33675 </B></U>&nbsp;&nbsp;<B><BR>
(Commission <BR>
File Number)</B> </FONT>
</TD>
     <TD WIDTH="33%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><B>84-1553387</B></U>&nbsp;&nbsp;<B><BR>
&nbsp;&nbsp;&nbsp;(IRS Employer<BR>
&nbsp;Identification No.)</B> </FONT>
</TD></TR>
</TABLE>
<BR>


<TABLE WIDTH="100%" CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER">
<TR VALIGN="BOTTOM">
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="50%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><U><B>1585 South Perry Street, Castle Rock, CO</B></U><B><BR>
(Address of principal executive offices)</B> </FONT>
</TD>
     <TD WIDTH="50%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="3">&nbsp;&nbsp;<U><B>80104</B></U>&nbsp;&nbsp;<B><BR>
(Zip Code)</B> </FONT>
</TD></TR>
</TABLE>
<BR>




<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Project" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Registrant&#146;s
telephone number, including area code (303) 794-2000</B> </FONT> </P>
<BR><BR>
<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 5-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;&nbsp;]</FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 5-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;&nbsp;]</FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 5-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;&nbsp;]</FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 5-TNR" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;&nbsp;]</FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) </FONT></TD>
</TR>
</TABLE>
<BR>
<BR><BR>




<!-- MARKER PAGE="; page: 41" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>
<DIV STYLE="page-break-after:always"></DIV>






<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 8.01 &nbsp;&#151;
&nbsp;Other Events </FONT></H1>



<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>&nbsp;&nbsp;&nbsp;&nbsp;On
June 26, 2008, the Registrant issued a press release titled; &#147;AspenBio Pharma
Commences FDA Clinical Trial for AppyScore&#153; Appendicitis Blood Test&#148;.&nbsp; A copy of
this press release is attached hereto as Exhibit 99.1. </FONT></P>



<BR><BR>
<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 9.01&nbsp;
&#151;&nbsp; Exhibits. </FONT></H1>



<!-- MARKER FORMAT-SHEET="Para (List) Hang Lv 0-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit <BR>No. </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Description  </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para (List) Hang Lv 0-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.1 </FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Press
release dated June 26, 2008 titled, &#147;AspenBio Pharma Commences FDA Clinical Trial for
AppyScore&#153; Appendicitis Blood Test&#148; </FONT></TD>
</TR>
</TABLE>
<BR>
<BR><BR><BR><BR><BR><BR>
<!-- MARKER PAGE="; page: 1" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>
<DIV STYLE="page-break-after:always"></DIV>


<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURES </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>


<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH></TH>
 <TH></TH>
     <TH></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="45%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
<BR>
Date: &nbsp; June 26, 2008<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></TD>
     <TD WIDTH="40%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
AspenBio Pharma, Inc.<BR>
(Registrant)<BR>
<BR>
<U>/s/ Jeffrey G. McGonegal</U><BR>
Jeffrey G. McGonegal<BR>
 Chief Financial Officer<BR> </FONT>

</TD>
     <TD WIDTH="15%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
&nbsp; </FONT>
</TD>
</TR>
</TABLE>
<BR><BR><BR>
<BR><BR><BR><BR><BR><BR><BR>

<!-- MARKER PAGE="; page: 1" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>
<DIV STYLE="page-break-after:always"></DIV>






</BODY>
</HTML>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>appy_8k-ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Head Right-TNR" FSL="Project" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit 99.1 </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><IMG SRC="appylogo.jpg"> </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Minor Center Bold-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>AspenBio Pharma
Commences FDA Clinical Trial for AppyScore&#153; Appendicitis Blood Test </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Minor Center Bold-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>FDA 510(k) Clinical
Trial Launched with Patient Enrollments Conducted According to AppyScore Protocols at
Participating Hospitals </I> </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>CASTLE ROCK, CO., June 26,
2008</B> &#151; <B>AspenBio Pharma, Inc.</B> (Nasdaq: <U>APPY</U>) an emerging
bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for
humans and animals, has officially initiated a clinical trial to support the FDA 510(k)
application for the AppyScore&#153; Human Appendicitis blood-based diagnostic test. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Enrollment of the first patients in
the independent, blind, multicenter study began this week, which will include patients
from a large children&#146;s hospital. The study is focused on patients arriving at
hospital emergency rooms with a primary complaint of abdominal pain. This is further
narrowed with criteria related to medical history and duration and location of abdominal
pain. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>To help insure a successful trial,
AspenBio engaged a highly qualified and experienced Contract Research Organization
(&#147;CRO&#148;) to plan and direct the trials. Clinical teams have been assembled and
include principal investigators, co-investigators, monitors, technicians, statisticians
and coordinators. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Clinical studies provide data
regarding clinical accuracy and usefulness. Key study endpoints in the trial will be
AppyScore&#146;s sensitivity, specificity, negative predictive value, positive predictive
value and appendicitis prevalence. The company must prove the clinical performance
characteristics of the final device to support the proposed intended use statement as an
aid in the diagnosis of appendicitis. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Following consultations between
AspenBio management, the CRO and the independent statisticians, a determination was made
to increase enrollment of the clinical trial to approximately 800 patients. This is
expected to provide higher statistical power allowing for more definitive support of the
AppyScore&#146;s test performance and medical value. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>In addition to performance results in
the clinical trial, AppyScore&#146;s 510(k) clearance process also requires the submission
of a non-clinical data package. Non-clinical studies are required to demonstrate assay
performance characteristics, like accuracy and precision. The company is in the final
stages of completing this non-clinical section for the 510(k) submission package. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Based upon the rate of recent pilot
patient enrollments, AspenBio expects the FDA clinical trial to be completed in
approximately four to six months and thereupon, the company plans to submit the results to
the FDA as part of a final data package. After the data has been successfully reviewed by
the FDA, final steps will include determining the product label claims, which are also
subject to FDA approval. The company looks to complete this process and anticipates FDA
510(k) clearance in early 2009. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Right-TNR" FSL="Project" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Page 1 of 3</I> </FONT></P>



<!-- MARKER PAGE="; page: 1" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>

<DIV TITLE="EE+ Page Break" STYLE="page-break-after:always;"></DIV>



<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>AspenBio Pharma president and CEO,
Richard Donnelly, stated: &#147;The initiation of this clinical trial is a major milestone
for AspenBio in our efforts to commercialize the first and only known blood test for human
appendicitis and what has been heralded by analysts as a medical break -through. We are
encouraged by the pilot results we have achieved to date, and we have great confidence in
the highly experienced and professional team overseeing this trial process and FDA
submission.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>While the company remains optimistic
that the AppyScore test will be successful in achieving FDA clearance, since the trial is
a totally blind independent clinical study, the final data and successful clinical
performance cannot be assured or known until the study is completed. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Meanwhile, AspenBio continues to
advance AppyScreen&#153;, a second generation, revised format point-of-care version of the
appendicitis test. AppyScreen is a rapid appendicitis blood screen test designed for use
in physician offices and urgent care facilities throughout the world. Many children and
young adults complaining of abdominal pain are taken to their family physician&#146;s
office or an urgent care facility for medical attention rather than to a traditional
hospital emergency room. The AppyScreen blood test system is designed as a valuable new
screening tool to help physicians make better decisions on ruling out appendicitis
conditions or recommending patients have further work-up at the hospital emergency room. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Before year-end, the company looks to
complete the development of this simplified point-of-care test version AppyScreen, which
preliminarily has been able provide results significantly more rapidly than the
first-generation AppyScore. The company has executed agreements to have a final prototype
of this device developed in 2008. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>AspenBio continues to seek a
potential worldwide licensing partnership or transaction for AppyScore in the upcoming
months, and would accelerate that process upon the successful completion of the clinical
trial and submission of the final package for FDA 510(k) clearance. While the exact timing
of these events cannot be determined, the company looks to achieve a worldwide licensing
partnership or transaction prior to the FDA 510(k) clearance for AppyScore. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P>
<FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About AspenBio Pharma,
Inc.
</B><BR>AspenBio Pharma is an emerging
bio-pharmaceutical company dedicated to the discovery; development, manufacture, and
marketing of novel proprietary products, including those that enhance the reproductive
efficiency of animals and that have large worldwide market potential. The company was
originally formed to produce purified proteins for diagnostic applications and has become
a leading supplier of human hormones to many of the nation&#146;s largest medical
diagnostic companies and research institutions. The company has successfully leveraged
this foundational science and technology expertise to rapidly develop an enviable
late-stage pipeline of several novel reproduction hormone analogs for wide-ranging
therapeutic use initially in bovine and equine species. AspenBio Pharma continues to
advance the development and testing of its two first-generation blood-based human
diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients
complaining of abdominal pain. For more information, go to
<U>http://www.aspenbiopharma.com</U>. </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Right-TNR" FSL="Project" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>Page 2 of 3</I> </FONT> </P>



<!-- MARKER PAGE="; page: 2" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>

<DIV TITLE="EE+ Page Break" STYLE="page-break-after:always;"></DIV>





<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P>
<FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Forward Looking
Statements

</B><BR>This news release includes
&#147;forward looking statements&#148; of AspenBio Pharma, Inc. (&#147;APPY&#148;) as
defined by the Securities and Exchange Commission (the &#147;SEC&#148;). All statements,
other than statements of historical fact, included in the press release that address
activities, events or developments that APPY believes or anticipates will or may occur in
the future are forward-looking statements. These statements are based on certain
assumptions made based on experience, expected future developments and other factors APPY
believes are appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of APPY.
Investors are cautioned that any such statements are not guarantees of future performance.
Actual results or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including statements regarding the
ability to successfully complete the clinical trials and pivotal studies required for FDA
submission, obtain FDA approval for, cost effectively manufacture and generate revenues
from the appendicitis test as well as the animal products under this agreement and other
new products, execute agreements required to successfully advance the company&#146;s
objectives, retain the scientific management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment, fluctuations in sales
volumes, obtain and enforce intellectual property rights, and realization of intangible
assets. Furthermore, APPY does not intend (and is not obligated) to update publicly any
forward-looking statements. The contents of this news release should be considered in
conjunction with the warnings and cautionary statements contained in APPY&#146;s recent
filings with the SEC. </FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>For more information contact:<BR>
</B>AspenBio Pharma, Inc. <BR>Gregory Pusey, Chairman <BR>Tel 303-722-4008 </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Investor Relations: </B><BR>Liolios Group,
Inc. <BR>Geoffrey Plank or Ron Both <BR>Tel 949-574-3860 </FONT>
</P>


<BR><BR>


<!-- MARKER FORMAT-SHEET="Page Number Center" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2># &nbsp;&nbsp;#&nbsp;&nbsp;# </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Right-TNR" FSL="Project" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>Page 3 of 3</I> </FONT> </P>



<!-- MARKER PAGE="; page: 3" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>appylogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 appylogo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!(`-@#`2(``A$!`Q$!_\0`
M'``!``("`P$```````````````@)!PH$!08#_\0`,A````8"`@$#!`$"!04`
M`````0($!08'``,($1()%2$3%!8B00HC%R0E,6$8-411P?_$`!L!`0`"`P$!
M```````````````$!P,%!@@"_\0`*Q$``00"`@$#!`("`P```````P$"!`4`
M$082$P<4(14B,4$C,E&!%B3!_]H`#`,!``(1`Q$`/P#?XQC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8SX[-A
M-1#;=I@UDUAY;-AO@``/C^/D0$>OXS[94;ZO]Q7#"^->JHN/<7FDLN/D([[Z
M_;4=?L[P^2=GB!4@K)H]HDC0DV+2D.@#5&RKP`I=7O8&$QS&$2[>@IS7]U6T
MP#`COGR6B?*DOZ1X<=J*25-D.72-CQ(S"R"KM/M'UVG;LV%831UT,\PK'D8%
MBN\8TV0I'*C!!&W]D*1S6-3X^5W\ZUD$N?7KPH:PD;W4?$)GC<TDS"I5M$EM
MZ3=N4.:71.<R98BA#.BVZ"OYV\Q@$9.XG.PD.!@U,<@*80-6GP\YN^H1R\YC
M4I6SIR9L;2V2B>I'"5)&`K-&&+\+CX'DDC1BTQQN:$8@N8VG8V?^P\S_`,F'
MO"D0]%SU&)@WZ7370?XVEWE\M&N86#7+$Y?`@'_:5;^+T@'^0!S;?+KOH.@'
MJ5%)\1N9/IK0"_>3TRIN1I++CB:LX/66R(*V:>)DK`Z3MNF-J2]:6(.$D%AC
M_P"*04L(='1S`!`)P'\#\^SH]-Z0<>XY.HN+3.&WG*Y,,59#D39-39V,ZUM)
MD>L$=RR4*.,(+IRS#!BL$$,6*9Z#>YK4RHG2^43[$4VT9;P:X3_<&CQ@SXX`
MQ(NI+@L8)K%>K_"C'/<JJWLCD:JHK76,\Q/5#Y#>GWSA>*ZL*/M=N<<9HRQV
M?Q%MV(T,?GD<C+T4K*[)(U(T(@A?"LLD99%XMDE;";#)S:@&0%+T`7@\?;_J
MSDW5\=MVGI)JDD.D>C^UN-X)G1J<DQ""N8)"TAL,9D?FXY@U.;;M*7;J/WV4
MVHVLYZ`/7EKQBO;BAQRYD0+[=Q;F7>SZ5;LF*/\`FJYN9H0/,=7K#]]>W(WY
M(VM8%$`-Y3388!,`CXUV^A9RN>J8Y7MM)NKBH&MN0131[:W*3"1*TV&F1@LB
M3JD3!\_>N/B$9,`?J(O11$!$I<JZ1Z;U/+?28'+Z.&RJY;Q6--A\BBB:H(]D
M^CE/%/21&14&D_Z<,,P<D36J]?()XG.<A&=*._EUG*'U$TR2:NR>`L`A$7S1
MFS1-?%Z$VO8:E_A:-6M5N^W;XZYO"XQF+[6LZ(4Y6\VM&<+1;8C!(XYR=^7:
MR_<;R(&U(;:<J8@'\MJY7T32BUE$H;-ARD,8@&$Q?-PA%.8,<`WF.<H@!$-%
M<0A#$8(;&-3Y<]Q",:UJ?G?YWI%L-[VC8\CUZL&QQ'KK>F-_LO\`K?X_>90Q
MD5>*'+>H^9U8;[9IM0\;HVCD;I%%Z22-B5L?6I]:]2%9L1KD*5<YEU&,C7(%
MVH`W'$Q3D,82]=!*K,\V%,K9DFOL(IX4Z$9T>7$DL49XYV:[C(-?EJIM/S\_
MG:(J9\`.*0(9@$84)6-((HW=AD8[?5S7:3:+K_'^/TN,8QD7,N,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&>5E&B5JFO>FB+FR,[QL_72YO[0L?4:
M7L![,+2C=(^=6`=?'^J:NNQ[`W\:POK36=S0XO;J7WQCEW;"QHLS1."ONF)-
M,;JIM9EC`:."U(6;9!FY)*NUJ5T<BF_)).^E\]1?GR+^NU)E4'J]\/GGEQQ.
M>4$);A<K-J9R_P`2((VZ1$5C^=M1+4\@C*3]0#W!^8]FPC7\_#P5.'SY=Y8_
MI3=UM)S6@6[C5AZ8\Q(DYUA7198A^X$04<Y2R!D($0I+A/)X7B1Z?WVK6ZY[
MDT*1*IY_LWF;,8)I0>$Y@[\1!$<Q?$]G;OXT1%=OIV72+M472W;.9_+]G7Z7
M-#RHY#ZEVH!WCM-<=CJP$!^!`06R#H0$.^P$/Y^?CO-@F->L!;'$6.<185R+
MTJKU46/3B2V+ED&X4C79\2;+&DB]57"5H(C%&P+]C?!P;7!S024`W/!1,77(
MRB8W>N-0E0.]SWW5E)IDJC0Y3NQX]$%NH1^T4HTBEX^T>3"(CT`-Z'W(?GX#
MKOX_G*G/.TV^WN6=S2AAW`$3;9(,(@FD/_$@E<I$$0B"/H1_EE9Q$?GOY'L?
M]^_;_)^'<5Y7=5E#-I*DD4=98W4X\6.*&5JDZUE2-LJ,,4@+C2"3Y(O$=NS5
M@]H]/N'35=:V=7&-.'/DM*22"+'0ABG8KQ(61([#,\@W=$`(>E8NT*KMIUZO
MWE+6@U6<T^"LRA=1;6177=QU(MWUIN9D29M:D;D*4)!#E8M0`C*B!HE:-KVN
M#=X$$HZMFH_79O'1FX.-<@U<W.,C,ETJ$<B1W]7J<48])5214EF#?]Y_Q_D/
M_@_\9M#_`-/!.'^1<0+!A[INW;F>O+K>&Z*F,4/H(FI^CD=D:YI(/78]/:US
M=3!_M_K8`'SUG5\>/3)<H5ZLM[<B'I@^PI6).*RQZLWJ4I2HY!.;8;SKUZ=K
M$1#Q)`GI3)P$X`(E.:/!X_(YY^XKR"#Z7E]9>$6<Y#@A0ITNF?*7R&F'/`;7
M-#O2=I<T<ZM.1=+M(\LZ)K3$[FS@GY&G$;F,%@WG()LUHT^P+&J.4PNE5O\`
M&U8[QO7X5OD:[Y1J-785RBOUP;/<ME.5!Q/AKF"69\I[:CL76""@A")H>V.S
M<9;L=0Z\@;S2!PCYO(#=B+3L`1,(=A>IFMA>?$V6>HQZH<Q8[Q@EQQ;BY1E;
MFC+'*09GB&-LLD"<4)Q+#Y:ZL&UD?F]\>WIT<A]K$_ZL/EV(`(Y3_I>*K#RA
M+Z[DCB5?%8$N_,1_B>\DN-XX]8"/%*>/[R0ZQDQRCBM,/R^!6J]FT<G6<F?)
M=7>RAL\DFR,&$QJKT8@WD820\K^KN@VQQE:YVEUW1=+K6>@]/%$Q<+?4=Y*\
M&F9R';5]FQ./6S3ODZ&<TONK6SH%;PS)%8]#]\9B7.A1`>A,2$C\AW\=KR%Y
MN\K+!YY6#PTH.[*$XIH*S8FE2AEEW-J)8[6Q)GAEC[N#0Q'DC&[H0_22]M:!
MK0'VF!D,<V[:<PL9H]<H/3?U>GS;'%/DUPA@=XV:HA]K@>RXFVZ%=D/YV`OM
MH;?L4,<CY'%$W/$6V3*-NVSP`@%4Z`[`QNAR?ZALGIJT;.GD2Y->FOR:EFEM
M2HFVCN2=#1]2KDDJ;=[,WJ1!S5D(@0:P;WQ4Y$;&>2%FQ`\.PC9-A]ICVPV-
MQ^_Y'5\FC"9RP-_Q%T.9+F1Z5;.#R2ADP*F3=GXO9VCHTYYX;8TLD))A"O#)
M-/CO:43%3EO+.@U\FN,YU<^%:-(@1%GJ"173=R60Q64",XHU%V<QQW`;V5$7
MQ;5S62;Y`\D.?G%+T\K)MR[%-/?]0T-L:.,$>?HBS'<H8_P5VD<=:-<B6-1E
MX=N:XJMS$2`V,IM0%U",?U@.L#Q.M#F=ZM-6T;7?.23M-!)Z+<44)WOU(-[6
MI62OV%^Z3))A(W;8@.O9?R4=VHX_CTAV:F+ZVHHL!Q,<@8-L*!<B*[]"&?1[
MD?HEK.[EM>#N,`CLX5+@F,?KE7,H@5F97=,M+]VR&(N*Z^WM+D<3Z0-K\RE#
M<01YE@<C.2/,'AO3G`RG.'=VL$WDD8K&.S>PI@P*VFJT<,CZ-`M229ID8-X>
M3"^@C;'('9W%E\"@($!\\]GG*I^-5@Q-D?0^!7$%OJ)>5W(KWV\2)3Q^+A@U
M3'&K%DS6I"&%3O(TD=3FA/\`M&=B'<KL4NQDJY@_?7$,O_'J^3`B#>4DLED8
MKQL]RX07>?MO9.S!=T3X;\+UL&Y9>IR_I=/%BL.+RR`Q>S>6,*C]G(;'NYT3
MM->U37#\V+5@/+R=4!$9W(OM3P.HJX1*3V8"D87T[UK)JZ?A_P`[[Z+R\=N%
M7(^R:1OQRD\"43ZK;OHE:U^R+%"%N7/"V.R1*T$T->DY$#4[#K'6W:1U>R%`
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M`-03U1>6,3NE@IB-U.C=*N?I"[/MX2^/[&Z,L,79="_8T0&-QP!>4K].GL48
M]N+F8$^O0)B&(&DH/I;2_2_YCS?EKQ#_`,:+92LB.81F22R,258Q)A;6MTTQ
MA&WN@/!$1O(4`;$*XH#K^"$$GD!1,<W<.O2$J6TJWXZ\S66P:WGT(=I-9<V7
M1IJF$2D48<W]&JB2U(E5-*-Y0HA6AL,!-?DU@8H;#$`0\C$[XOI>P6X*@]+.
M[H_(JKL>-V*H?+D4L,*D$*D;#,G?WV,L30S*T<:6MR-]$1$O9?%L`?T,/?B0
MP#K_`%"'Q1:SG,>GI^.074').)CJ)=2D9)DH$^NG%MWD,.2190G'%%<H(K?;
M1E>J(P3B[)GX^MFDFG),E615G0;8DH4E?^N`@90?;J07X&O4I>J(Y>_5?ZHS
M2\",/-0R?CKNE#7<T^?N9,\>I"XU]%H/=D\_,T4S?9@XK(@S_@J.1^QH6]$A
M$@N0.;1T5C(<3&[.0`N70.,C)+J5B+[9[>VS!LA+])K"@*=J1+=]@)TK.R1Y
M6[^Z&,!F)MCLL>2.!3:0,+V;:764`+I..NLE]9VNRN,M>\<*KXU6TBMG2QUX
MRHK.F-)/%<-59.S$NCRMXGBV=R1N9EW:$4;B`"VF%[?!$0*4!'LTGKAA=H2B
M=<F5L-:I&,@8^'C#6%>/H)U*09%)Y*ML"0288V["8!,_D.FBNH0*!A+N/K`0
M\A$<H7.ZR5\2ORG)_*W*$0RPX_(Y0WE7;]S<V*5/]].V*OLG,S0M$@-[\#:M
M*!7(8^MW%)\#LZ`!$V*;MFMKJ;OJ:DZGF#-!-TLB5@3>625VA:6<BE:HQ[6A
M:$R5G5.;*7M:]NP>6P'(I@*4Q2!T(`;&E=)4EG6AQR6US`I5":KXY0R1?7<9
M?"7N"F,]R6'A!&>NXZT2)I9WU8>/H1<'*2N8$,R!L#20-QMFT@!SIC33K<7+
MJ5N<A66S#H?!Z5BD?C4J@THDE>E=WR3R9Q>I,UHY$R;$@O>M&A:&KW)O$Q@U
MCLUAL#L>@8S%KC>5S/#<]U6^2UMVS"(<NZSI_;9L(2*8@DE,6%G+9,C*K:`<
MGH(^X-["TNK5)RZW0VH"@(%$I?'RG9#[UINP&R7N\3L".NS17Z@=$P>2K12-
MC`!4!7;[U>X+2I$)686\WWX.@;19S:2"<-P^`@6)%I\88DXS#C/2D-B3XU4^
MS2:P['L?<W>[*TCLK0LS>B3(99+E(KEZ]PG+B\'UNY79R^L]-1-I![(76!<0
MV?$I/L;[<>W:O9H:"2CF;4[%+V"/P9V=5+K0%41F/LH;$,=9V\Z][AZ]ZCB`
M@>U-X@)3G#R,`?+&6!P3D?2MEK7AMATY3KW!DC@2]QT+FJ1,1B1;L4_Y*E&1
M-;2"YC\^P%S;3'T"(=CL_;Y,/(ZCY1MUZF&RHX[[=RV*-V@4"M2J3'<IVC%;
M$&H%)$8%!>_("D7:6XP_6*`@.P@`41&#+R:Y)3NYLVN[5I+H\[*Z!BE;TG%O
M:%RI_,V.B&9O)D@_9"M1+GTKX]-CE*&V/GV"R_VV#9L/N8@V#[VP^-B7:S\-
MN.C,QO*.OXK)%3]8#U'TBU*C!+#H(XBI1O#JC,`(?SR4+B`80.`[#=]>)0(`
M,9)?5RHX];F28R'5:D<W,T#<$C-)'/3]Z;4E<G/ZGV*-I`$0C(3+_M^T`1OW
MGZP@'B(@01STCQ>M3,,(CED.<T;-,/F!6T8J[Z?O')1*Q=$XJD*2.-#>A7/C
MTNW``F(VMK:?=T)C>`"79K+!I94[CIEO,^\`@TD%[B<25UAQ^C:&.JT^A.C8
M:I,S`\02-H4!06&<G)X_'&IU:B"46/6<A2E#Y+Q$S1*ZDM>@6O76<TG1X)Q.
M9XI5C2A8%N^+H[;D+R"&=*Y#)?;P8X(9&S-#41R<W(Q>V8W0")NBF8RQF"6!
M%K*8?R:$O`N[,92K;_K"D7-JE,M;%)DRQ&J;'A&A<$2LAB"4=;AJ(?OQ-X%U
MCV+,)\.6>:-W'^(J+&2N"*=R)QG$OE:-P2+&Q41VF4ZD,E-YHE@BL0AX.!#`
M0_7P;S_8/'IC&2IQC&,96):'IH4T]7@\\K:F2)J^O_9"K!:&W</6NOG*=S",
MK(XT6*^,Z9$=:AD3(*O88SI'CZ-KL0Q2[=9C@;8;7()_3^\[E,SU,Z]SI/V'
M<IZ5SO\`-W=2UBG_`(4%:#,`2<3B/QX^V_`]=]?QNY8RS^,>L'.>*".*!81Y
MC31(L%K[>,M@<$2$LA8D<)GE8_PQUE2/&QZO1$)K\(B9S5EQ*ELU$I0/!XC$
M/UBO\+'E+T\CW-1%V]_C9V=OYZI\)^X9\'N($.X44#'*6B;FID"O2L5R*:RU
M2F!N52J9N8)"N[J9$0IBH40D1(D#8VEV_3TM6C44!V?L)IF8QE>6-A-MK";:
M6,DDN?8222Y<DJ[(8Y5V1[E^$^Y?TB(B?A$UF_C@%%`*,!G0(&(,3-[1K&II
MK?\`7_N,8QD/,V,8QC&5[>IOQOL?EAQ$GE)U/^._FL@>H4X-PR9T.S-?T&"2
MMKPK*=:1`N\3&1I=@%#Z8`8WZ]E,!2&DWQ^A;U6M&U#7\E^U&00JN(G%WG[%
M092E!R861&B5_;JA`!.0=FD?$WQY`(>(B4`,.;L9MB7<XM%%XX_VWTZ)92[8
M2H#4OWDV*"(=7R/(O8?CCM\;/&GC[$^YW95R$V!'9.-8-1_N#QX\5_9VV(".
M52-:QFDZ=E<J.7:[^U?RWY8QC-3DW&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
- -,8QC&,8QC&,8QC/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
